Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia. URAPIDIL is a small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications. It is grouped under the following drug class(es): Alpha-1 Blockers. Its therapeutic use is listed as antihypertensives and cardiovascular. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Ebrantil, Eupressyl, Mediatensyl and Uraprene. Its PubChem CID is 5639.
Urapidil
| CAS No | 34661-75-1 |
|---|---|
| Molecular Formula | C20H29N5O3 |
| Molecular Weight | 387.50 g/mol |
| Synonyms | 6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Urapidil has been investigated for the treatment of Hypertension During Pre-Eclampsia. URAPIDIL is a small molecule drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications.
The listed CAS number is 34661-75-1.
The listed molecular formula is C20H29N5O3.
The listed molecular weight is 387.50 g/mol.
6-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propylamino]-1,3-dimethylpyrimidine-2,4-dione.
The source lists Ebrantil, Eupressyl, Mediatensyl and Uraprene.